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Abstract
Background: Currently there is no effective treatment available to retard cyst growth and to
prevent the progression to end-stage renal failure in patients with autosomal dominant polycystic
kidney disease (ADPKD). Evidence has recently been obtained from animal experiments that
activation of the mammalian target of rapamycin (mTOR) signaling pathway plays a crucial role in
cyst growth and renal volume expansion, and that the inhibition of mTOR with rapamycin
(sirolimus) markedly slows cyst development and renal functional deterioration. Based on these
promising results in animals we have designed and initiated the first randomized controlled trial
(RCT) to examine the effectiveness, safety and tolerability of sirolimus to retard disease
progression in ADPKD.
Method/design:  This single center, randomised controlled, open label trial assesses the
therapeutic effect, safety and tolerability of the mTOR inhibitor sirolimus (Rapamune®) in patients
with autosomal dominant polycystic kidney disease and preserved renal function. The primary
outcome will be the inhibition of kidney volume growth measured by magnetic resonance imaging
(MRI) volumetry. Secondary outcome parameters will be preservation of renal function, safety and
tolerability of sirolimus.
Discussion: The results from this proof-of-concept RCT will for the first time show whether
treatment with sirolimus effectively retards cyst growth in patients with ADPKD.
Trial registration: NCT00346918
Background
Autosomal dominant polycystic kidney disease (ADPKD)
is the most common hereditary cause of end-stage renal
disease (ESRD), affecting all ethnic groups worldwide,
with an incidence of 1 in 500 to 1 in 1000 [1]. ADPKD is
characterized by the progressive development of innumer-
able cysts in both kidneys, which distort the normal kid-
ney architecture and leads to a loss of renal function. The
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development of renal failure is highly variable, but typi-
cally patients develop ESRD by the age of 40 to 50 years,
necessitating renal replacement therapy (RRT) and/or kid-
ney transplantation [2]. Apart from blood pressure con-
trol and symptomatic treatment of cyst bleedings and
infections there is no curative therapy for this disease [3].
PKD1 and PKD2 encode the proteins polycystin-1 and
polycystin-2 which are expressed in the kidney and func-
tion together to regulate growth and morphologic config-
uration of renal epithelial cells [4]. Mutation in PKD1
leads to a more severe phenotype of ADPKD than muta-
tions in PKD2, with ESRD occurring on average 20 years
earlier (53.4 versus 72.7 years) [5].
In ADPKD progressive cyst growth generally precedes the
development of renal insufficiency. Compensatory mech-
anisms (hyperfiltration) maintain renal function virtually
normal for decades despite continuous cyst growth. By the
time renal function starts to decline, the kidneys are usu-
ally grossly enlarged with little normal renal parenchyma
recognisable on imaging studies. Data from the consor-
tium for radiologic imaging studies of polycystic kidney
disease (CRISP) and others have shown that the rate of
kidney volume growth is a predictor of renal functional
decline and therefore kidney volume is used as surrogate
marker of disease progression especially in clinical inter-
vention trials for ADPKD [6,7]
Non-invasive radiologic methods are available to monitor
the growth rate of kidney volume. Renal ultrasound meas-
urements are operator-dependent and not precisely repro-
ducible. Unenhanced and contrast enhanced Computer
tomography (CT) scanning is reported to be an accurate
method to determine kidney volume, but it involves ion-
izing radiation and potentially nephrotoxic contrast
medium and is therefore not an ideal method in patients
with reduced kidney function needing repetitive measure-
ments [8,9]. Due to its high soft tissue contrast and the
lack of ionizing irradiation Magnetic resonance imaging
(MRI) is also considered useful to monitor kidney volume
changes in ADPKD. The analysis of sequential MRI scans
was shown to be accurate to monitor rates of kidney vol-
ume enlargement in ADPKD [7].
Sirolimus is an immunosuppressant that binds to FK
Binding Protein-12 (FKBP-12) and inhibits the activation
of the mTOR, a key regulatory kinase of growth and pro-
liferation. Sirolimus is approved for the prevention of
graft rejection following renal transplantation. Due to its
antiproliferative properties it is also used in coated stents
to prevent coronary artery restenosis after angioplasty
[10]. Furthermore it has shown clinical effectiveness in
kidney transplant recipients with Kaposi's sarcoma [11].
We have shown previously that the mTOR inhibitors
rapamycin and everolimus effectively reduce cyst growth
and loss of renal function in an experimental animal
model for PKD [12,13]. Additional studies have shown
that rapamycin is also effective in various mouse models
of polycystic kidney disease, including dominant and
recessive forms [14]. Of interest, an analysis of ADPKD
patients which received a renal transplant, revealed that
cystic kidney volumes regressed under immunosuppres-
sion with sirolimus [15]. Based on these promising results
we have designed and initiated the first clinical trial to
examine the effectiveness and safety of sirolimus in young
patients with early manifestations of ADPKD and intact
renal function.
Methods/Design
Study aim
The primary objective of the SUISSE ADPKD study is to
assess the effectiveness of sirolimus to retard kidney vol-
ume growth and to prevent the loss of renal function in
young patients with ADPKD and preserved renal function.
Patients with ADPKD and kidney volume growth that can
be documented within 6 months are randomized to treat-
ment with sirolimus 2 mg/day for 18 months (Figure 1) or
standard treatment. The secondary objectives are to follow
renal function and blood pressure and to monitor for the
occurrence of proteinuria. Safety and tolerability of
sirolimus treatment in ADPKD patients will also be
assessed.
Study design and setting
The study is a single center randomised controlled open
label trial which is open to ADPKD patients with a posi-
tive family history of ESRD due to ADPKD thereby select-
ing mostly patients with mutations in the PKD1 gene. The
study will involve 100 ADPKD-patients aged 18–40 years
with a creatinine clearance >70 ml/min. Kidney volumes
will be measured by MRI without contrast media at study
month 0 and 6. Patients with documented volume pro-
gression are randomized at a 1:1 ratio to sirolimus 2 mg/
day or standard treatment for 18 months. Recruitment has
started in May 2006 and will last until December 2007.
The study will be completed by December 2009.
Ethical considerations
Ethical approval has been obtained form the local ethics
committee of the University Hospital Zürich.
Study drug and dosing
Rapamune® (sirolimus) will be used at a fixed dose of 2
mg daily to achieve sirolimus through levels between 4–
10 µg/L. By using this rather low dose of sirolimus as
monotherapy we expect a low incidence of sirolimus-
related adverse events. The dose will be reduced or with-
held in case of a through level exceeding 10 µg/l, elevatedBMC Nephrology 2007, 8:13 http://www.biomedcentral.com/1471-2369/8/13
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liver enzymes (> 2-fold above normal values), thrombo-
penia (< 100'000/mm3), leukopenia (< 3'000/mm3) or
serious sirolimus-associated toxicity.
Study drug adherence
Adherence to the prescribed study drug will be assessed by
using the Medication Event Monitoring V Track-Cap Sys-
tem (MEMS®, Aardex, Ltd., Zug, Switzerland) during the
complete treatment period. The MEMS® assesses the med-
ication adherence reliably and sensitive as a period with a
lack of medication bottle opening documentation, repre-
senting most likely an episode of non-adherence [16,17].
The system monitors electronically the date and time of
the medication bottle opening. We will measure 1) treat-
ment adherence as the proportion of medication vial caps
opened in a given month relative to the prescribed doses
for that month, 2) dosing adherence as the percentage of
days with correct dosing and 3) drug holidays, as the
number of periods without drug intake that exceeded 48
hours.
Identification of eligible patients
Study participation is offered to all eligible patients with
ADPKD. ADPKD patients suffering from advanced renal
failure including dialysis patients and transplant recipi-
ents treated at our clinic are informed about the study and
screening for ADPKD is offered to their relatives. All neph-
rology clinics and dialysis units in Switzerland have been
informed and information material (print and in the
internet [18]) for study participants and health profes-
sionals has been provided. Potential study participants are
invited for a screening visit including medical history,
physical examination, renal ultrasonography and blood
and urine analyse.
Male or female ADPKD patients aged 18 to 40 years with
a creatinine clearance ≥ 70 ml/min are eligible for the
study if they exhibit a kidney volume progression over the
observational pre-randomisation period of 6 months. The
diagnosis of ADPKD is based on ultrasonographic diag-
nostic criteria in patients with a family history of poly-
cystic kidney disease [19]. In patients with negative family
history, proof of a mutation in the PKD1 or PKD 2 genes
is required for inclusion (sequencing analysis; Athena
Flow chart of SUISSE ADPKD study Figure 1
Flow chart of SUISSE ADPKD study.BMC Nephrology 2007, 8:13 http://www.biomedcentral.com/1471-2369/8/13
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Diagnostics, Inc., Worcester, MA, USA). Detailed study
inclusion and exclusion criteria are given in table 1 and 2.
Randomization and study blinding
Patients are randomized at a one to one ratio to sirolimus
or standard treatment alone. The randomisation list has
been generated by a biostatistics unit which is independ-
ent of the study team using a permuted blocks design with
a random block size of 4 and 6 to guarantee a balanced
allocation. The randomisation codes are kept in sealed
sequentially numbered opaque envelopes and are not
opened until two MR scans within 6 months have shown
an enlargement of the total kidney volume of ≥ 2 %.
Primary outcome
The primary objective of the SUISSE ADPKD study is to
determine the effect of sirolimus treatment on kidney vol-
ume enlargement in ADPKD patients with preserved renal
function. Patients with documented kidney volume
growth in the last six months will be randomized to
sirolimus or standard treatment. Kidney volume will be
measured 6 and 18 months after randomization and the
percent annual growth of the combined (left and right)
kidney volume will be calculated.
Secondary outcome
Absolute kidney volume growth from inclusion to month
18 will be assessed as a secondary outcome. Other second-
ary objectives are to compare blood pressure, renal func-
tion and proteinuria in patients with sirolimus or
standard treatment and to assess safety and tolerability of
sirolimus treatment. New onset or progression of arterial
hypertension might reflect disease progression of ADPKD
or a potential adverse drug effect and will be assessed
comparing the change of blood pressure and the change
of antihypertensive drug dosage during follow up. Renal
function will be assessed by using estimation equations
(Cockcroft-Gault and cystatin C) as well as measured cre-
atinine clearance determined by 24-hour urine collection.
Proteinuria will also be measured by 24-hour urine collec-
tion. The frequency and severity of all reported adverse
events will be recorded, including laboratory abnormali-
ties such as anemia, thrombocytopenia and hyperlipi-
demia.
Magnetic resonance imaging
All individuals undergo MR imaging of the kidneys using
a 1.5 Tesla scanner. For signal reception in all examina-
tions an 8-channel anteroposterior phased-array surface
coil (torso array coil) is placed around the patient and
covers the entire kidneys. The imaging protocol includes
unenhanced sequences only. In order to get an overview
of the extent of the cystic disease of the kidneys a coronal
single shot fast spin echo (SSFSE) sequence is acquired in
breath hold technique. The MR imaging parameters of
this sequence are as follows: repetition time (TR) msec/
echo time (TE) msec 1349/90.1; field of view 48 × 48 cm;
acquisition matrix 384 × 224; section thickness 4 mm; no
interslice gap. Based on this coronal sequence the transax-
ial sequences are planned. The transaxial sequences con-
sists of two breath hold T1-weighted fast spoiled gradient
echo (FSPGR) sequences (TR msec/TE msec = 85/1.4)
with two different slice thicknesses (3 and 4 mm, respec-
tively). Other parameters of the T1-weighted gradient-
echo pulse (GRE) sequences are: field of view 48 × 48 cm,
matrix 256 × 160; no interslice gap. In addition a transax-
ial T2-weighted fast spin echo (FSE) sequence with respi-
ratory triggering is performed (TR msec/TE msec = 17143/
102.8; field of view 48 × 48 cm, matrix 256 × 160, thick-
ness 3 mm; no interslice gap). To measure the kidney vol-
umes the transaxial breath hold T1-weighted FSPGR
sequence with a slice thickness of 3 mm is primarily used.
In case of a more advanced disease with large polycystic
kidneys and/or when respiratory artefacts are present the
volume measurements are either performed on the
transaxial breath hold T1-weighted FSPGR sequence with
a slice thickness of 4 mm or on the transaxial T2-weighted
FSE sequence. Once one of these sequences is chosen the
Table 2: Study exclusion criteria
• Female patient of childbearing potential who is unwilling to use 
effective means of contraception
• Increased liver enzymes (2-fold above normal values)
• Hypercholesterolemia (fasting cholesterol > 8 mmol/l) or 
hypertriglyceridaemia (> 5 mmol/l) not controlled by lipid lowering 
therapy
• Granulocytopenia (white blood cell < 3,000/mm3) or 
thrombocytopenia (platelets < 100,000/mm3)
• Infection with hepatitis B or C, HIV
• History of malignancy
• Mental illness that interferes with the patient ability to comply with 
the protocol
• Drug or alcohol abuse within one year of baseline
• Co-medication with strong inhibitor of CYP3A4 and or P-gp like 
voriconazole, ketoconazole, diltiazem, verapamil, erythromycin or 
with a strong CYP3A4 and or P-gp inductor like rifampicin
• Known hypersensitivity to macrolides or Rapamune®
• Patients who are unwilling or unable to give informed consent
Table 1: Study inclusion criteria
• Age 18 to 40 years
• GFR ≥ 70 ml/min (Cockcroft - Gault formula)
• Diagnosis of ADPKD:
❍  Positive family history for ADPKD
■  patients < 30 years: ≥ 2 cysts in either kidney
■  patients ≥ 30 years: ≥ 2 cysts in each kidney
❍  Negative family history for ADPKD but sonographically cystic 
kidney disease: proof of a mutation in the PKD1 or PKD2 gene is 
required (Athena Diagnostics, Inc., Worcester, MA, USA)
• Documented kidney volume enlargement (MRI volumetry)
• Signed informed consentBMC Nephrology 2007, 8:13 http://www.biomedcentral.com/1471-2369/8/13
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same sequence is used for volume measurements in the
following MR imaging sessions.
Renal volume measurements
Two independent trained observers perform a manual
segmentation of both kidneys for each patient. To prevent
bias, the observers are blinded to all clinical and radiolog-
ical data, their first measurements and the results of the
other observer. The measurements are performed in ran-
dom order. Blinding is performed with regard to patients
and the different time points when imaging has been
obtained. Manual segmentation is performed electroni-
cally on an interactive workstation (Advantage Windows
Workstation; GE Medical Systems Europe, Buc, France).
Each kidney is assessed separately. On each section, the
outlines of the kidney are manually drawn by using the
computer mouse. The vessels and the ureter in the area of
the renal hilum are excluded from manual volumetric
marking. The volume corresponding to each outline is
obtained by multiplying the area of the outline by the sec-
tion thickness. The total volume of the kidney segments is
obtained by summing the volume of each section. The
manufacturer's software automatically calculates the total
volume after drawing the outlines of the kidney on all sec-
tions. Mean values of the measurements performed by the
two independent observers will be used for analysis. In
case of a large disagreement, both observers will repeat
measurement.
Data collection
Data will be collected into a web-based data base designed
to capture all visit information including medical history,
results form laboratory analysis and adverse events. Base-
line data and ongoing data collection as outlined in table
3 will be obtained.
Patient follow-up procedures
Study duration for all patients will be 24 months in total,
consisting of a 6 months pre-randomisation observa-
tional period and 18 months follow up after randomisa-
tion (Figure 1). Four main study visits including kidney
MRI and 24 h urine collection will take place at baseline,
month 6, 12 and 24. Randomisation and inclusion in the
study takes place after evaluation of kidney volume
growth from baseline to month 6 within 2 weeks after the
second MRI. Three additional visits including clinical
assessment and blood and urine chemistry will take place
at month 9, 15 and 18. Patients in the treatment arm will
have four extra visits at week 2, 4, month 1 and 2 after ran-
domisation to allow for blood level monitoring and
potential dose adjustment of the study medication.
Patients without volume progression during the pre-ran-
domisation period will be followed by MRI for additional
6 months and enrolled if kidney volume enlargement is
detectable.
Study withdrawal
Patients will be censored and withdrawn from follow-up
at their request. Patients will also be censored if they are
not randomized after the pre-randomization observation
period.
Statistical analysis
Principal analysis will be undertaken using an intention-
to-treat approach. A secondary on-treatment analysis will
also be performed. The annual percent change in kidney
volume will be determined by regressing the log trans-
formed total kidney volume at month 6, 12 and month 24
against time for each patient through the least squares
method. Mean annual decline of renal function will be
calculated by regressing GFR or creatinine clearance
against time. All primary and secondary end point varia-
bles will be compared using a two-sided α-level of 0.05.
To account for possible baseline imbalances, a secondary
analysis will be performed in which comparison of treat-
ment groups for all endpoints will be adjusted for prede-
fined covariates using multiple regressions. The
predefined covariates are age, sex, presence of hyperten-
sion, medication with angiotensin converting enzyme
inhibitors or angiotensin receptor blockers, baseline total
kidney volume and percentage kidney growth during the
pre-randomisation period.
Table 3: Baseline and ongoing data collection
Baseline data and follow-up data at month 6, 12 and 24
MRI kidney volumetry
Creatinine clearance and estimated GFR (Cockcroft-Gault)
Proteinuria (24-hour urine and spot urine)
Physical examination and vital signs
Laboratory tests
Haematology/Biochemistry
Lipid profile
Sirolimus trough level
Pregnancy test1
Serological testing for hepatitis B, C and human immunodeficiency 
virus (HIV)1
MEMS® check
Adverse events and concomitant therapy
Follow-up data every 3 months
Serum creatinine
Proteinuria (spot urine)
Physical examination and vital signs
Laboratory tests
Haematology/Biochemistry
Lipid profile
Sirolimus trough level
Adverse events and concomitant therapy
1Only at baseline and month 24BMC Nephrology 2007, 8:13 http://www.biomedcentral.com/1471-2369/8/13
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Sample size considerations
In a large cohort of ADPKD patients, the mean annual kid-
ney volume growth rate was 5.27% ± 3.92% (SD)[7].
Because patients with lack of progression during the pre-
randomisation period will be excluded from our study, we
expect to select for a higher progression rate in our study
population. Due to a shorter observation interval com-
pared to the mentioned observational study, the standard
deviation might be higher. Presuming an annual kidney
growth rate of 6% ± 4.75% (SD) in the control group, a
sample size of 40 patients per group will have 80% statis-
tical power to detect a 50% relative reduction of kidney
volume growth using a two-sided α-level of 0.05. To
account for a drop out rate of up to 20%, we plan to ran-
domise a total of 100 patients.
Discussion
The SUISSE ADPKD study seeks to determine if sirolimus
halts kidney volume growth in patients with ADPKD early
in the disease course. Study participation is restricted to
young patients with preserved kidney function because
any effective treatment of ADPKD needs to be started early
in the course of the disease to have an impact on long
term kidney function. Our trial is the first clinical study
addressing this question. If sirolimus treatment can
reduce or stop volume growth in patients with main-
tained kidney function and prior documented kidney vol-
ume progression, these ADPKD patients could benefit the
most from a treatment with an anti-proliferative agent like
sirolimus. Similar studies using specific mTOR inhibitors
to halt disease progression have been announced by oth-
ers (Mayo Clinic, USA; Certican®  trial, Novartis, Ger-
many). We anticipate that sirolimus might be an effective
therapeutic option for ADPKD patients that are prone to
progress to end-stage renal disease.
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